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Abstract:  A  new  immunosensor  is  presented  for  human       against   the  logarithm-hCG   concentration  for  0.1–25 ng/ chorionic  
gonadotropin  (hCG),  made  by  electrodeposit-       mL with limit of detection  of 0.016 ng/mL.  High selectivi- ing    chitosan/gold-
nanoparticles    over    graphene    screen-       ty  was  observed  in  blank  urine  and  successful  detection printed   electrode   (SPE).   The   
antibody   was   covalently       of  hCG  was  also  achieved  in  spiked  samples  of  real  urine bound  to  CS  via  its  Fc-terminal.  The  
assembly  was  con-       from  pregnant  woman.  The  immunosensor  showed  good trolled by electrochemical  Impedance Spectroscopy 
(EIS)       detection   capability,   simplicity   of   fabrication,   low-cost, and  followed  by  Fourier  Transformed  Infrared  (FTIR).       
high sensitivity and selectivity. 
The     hCG-immunosensor     displayed     linear     response 
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1 Introduction 
 
Immunosensors make use of antigen-antibody  interac- tions [1, 2] 
to detect a wide range of analytes which are of great interest in 
medical diagnostics, environmental anal- ysis, and forensic 
medicine [3, 4], including pathogens [5], drugs [6], bacteria [7], 
toxins [8], and biomarkers [9]. Overall, immunosensors employ 
the same chemical ap- proach of earliest immunoassays, but offer 
quicker and simpler analytical procedures that may be  conducted  
at the point-of-care [10]. Immunosensors use an antibody 
immobilized as a transducer. Antigen-antibody binding event  
result in  electrical  or optical changes. 
The interaction of the antigen with the immobilized an- tibody 
may be monitored using several  detection  meth- ods. In this 
context, electrochemical immunosensors are increasingly being 
used for biosensing applications [11]. Electrochemical impedance 
spectroscopy (EIS) is an elec- trochemical  technique,  facilitating  
label-free  detection [12, 13], thereby yielding significant  
advantages  in terms of simplicity and rapidity compared to 
conventional im- munosensing processes. 
The immobilization of an antibody on the transducer element is 
a crucial step in the preparation of immuno- sensors [14, 15]. 
Physical adsorption is the simplest immo- bilization method, but it 
suffers from random antibody orientation and poor reproducibility 
[16–18]. Approxi- mately 90 % of the antibodies are in an inactive 
orienta- tion, due to steric blocking of antigen  binding  sites  on 
these antibodies [12, 19]. More-stable and reproducible antibody 
binding is achieved by covalent attachment, but this attachment 
must ensure that antigen binding sites are kept free [20]. For this 
purpose, antibody coupling to pro- tein G/A has been used   [21]. 
An alternative (simple and effective) method for Ab attachment 
uses chemical activation of the carboxylic groups at the Fc 
terminal of the antibody and subsequent covalent binding to the 
physical support [21, 22].  Al- though the antibodies may  suffer  
from  cross-linking  by this process, the sensitivity and the 
reproducibility of such immunosensors are both enhanced when 
compared to random adsorption [21, 22] and the simplicity of the 
over- all process dramatically improves  when  compared  to other 
oriented-binding approaches. Such Ab modification requires 
subsequent binding to a transducing support car- rying  an  amine 
layer. 
Chitosan (CS) is a biocompatible natural polymeric material 
displaying excellent film forming and adhesion ability [23], and 
thereby may act as an excellent amine surface for Ab binding. 
The solubility of CS is limited but it  may  be  achieved  by  
ensuring  acidic  conditions leading 
  
  
to the protonation of the multiple amine groups in the material 
(pKa of 6.3) [24, 25]. Moreover, the deposition  of CS films can be 
performed by  using  simple electrochemi- cal approach [25–27]: at 
a constant electrode potential, protons are consumed at the 
cathode, resulting in a pH gradient being established in the vicinity 
of the cathode surface and yielding a stable  and  reproducible  CS  
film. The limited electrical properties of this  film  are  con- toured 
by including highly conductive and biocompatible nanomaterials, 
such as gold nanoparticles (AuNPs) within the  CS  film [27]. 
The electrical properties of the transducing material to which the 
CS film is bound are also of major relevance in electrical 
immunosensing. The most widely employed electrode material 
has been gold, but carbon-based nano- structures are now gaining 
increasing interest. Different carbon nanostructures, with different 
inherent electrical properties have been employed in this context, 
mostly carbon nanotubes (CNTs) [28, 29]  and  more  recently 
(since 2005) graphene [30]. Graphene displays a combina- tion of 
interesting  properties,  such  large  surface  area, high electrical 
conductivity and biocompatibility [31–38]. Heterogeneous 
electron transfer (the transfer of electrons between graphene and 
molecule in solution, necessary for the oxidation/reduction of said 
molecule) occurs at the edges or at defects in the graphene 
basal plane [39]. Ad- ditional defects are introduced by 
functionalizing  gra- phene materials, a necessary procedure for the 
antibody attachment to graphene, also inducing electron transfer. 
Overall, graphene is a suitable electrical nanomaterial for electrode 
support in immunosensing, but it is mostly em- ployed as  a 
composite  material. 
Thus, this paper proposes a new approach for immuno- sensing 
using a combination  of  electrodeposition  of  CS and AuNPs on a 
graphene support  and  subsequent bind- ing of activated 
antibodies to  this  nanocomposite  film. This combination was 
used to follow the human chorionic gonadotropin (hCG) in urine, 
a 37 kDa glycoprotein hor- mone, secreted by the trophoblastic 
cells of placenta [40], acting as an important diagnostic marker of 
early preg- nancy. In healthy human serum and urine, the 
concentra- tion of hCG is extremely low. The increased level 
of hCG in serum and urine is associated with the trophoblastic 
cancer and many diseases related to  pregnancy  [41]. Levels can 
first be detected by a blood test about 11 days after conception 
and  about  12–14 days  after  conception by a urine test.  In  
general,  the  hCG  levels  double  every 72 hours, reaching its 
peak  in the  first  ~ 12 weeks  of preg- 
nancy  (~ 288 000 mIU/mL  or  ~ 58 mg/mL)  and  then  will 
decline and level off for the remainder of the pregnancy. Although 
there is no single “normal” hCG level in early pregnancy and there 
is  a  very  wide  range  of  hCG values as pregnancy progresses, a  
minimum  of  5 mIU/mL  hCG (or 1 ng/mL) is expected within the  
3rd  week of  pregnan- cy. The levels  of  hCG  may  also  be  
altered/increased  in the course of cancer diseases  [41]. 
Conventional methods for determining hCG are immu- 
noradiometric assays (IRMA) and enzyme-linked   immu- 
nosorbent assays (ELISA) [42]. IRMA is extremely sensi- tive, but 
involves radiation hazards, complicated washing procedures and 
is expensive, while the ELISA is less sen- sitive but time-
consuming. Several immunosensing  devi- ces for hCG have been 
reported in the literature so far [43–47], including different 
compositions and composite combinations, different detection 
methods and different strategies to enhance the number of free 
antigen-binding sites. Overall, the main  interest in point-of-care 
context  is to develop a simple and low cost procedure  for  the 
rou- tine determination  of  hCG,  where  the  complexity  by which 
the biosensor is assembled is of outmost impor- tance, mostly 
considering that immunosensing devices are of  single use. 
Thus, this work tries to establish a simple procedure at the 
stage of biosensor development, employing label-free 
electrochemical impedimetric detection. All chemical 
modifications made to the graphene electrode in a com- mercial  
SPE  have  been  optimized  and  characterized using EIS and 
FTIR. The analytical features of the final device have been 
evaluated in buffer and  urine  samples, and its applicability  tested 
in real  urine. 
 
2. Experimental 
2.1 Reagents and Solutions 
All chemicals used were  of  analytical  grade  and  water was 
mostly ultrapure grade.  Potassium  hexacyanoferrate III 
(K3[Fe(CN)6]), potassium hexacyanoferrate II (K4[Fe(CN)6]) 
trihydrate and magnesium chloride were obtained    from    
Riedel-deHaen;    CS,    AuNPs    (< 100 nm, 
99.9 %);   N-(3-dimethylaminopropyl)-N’-ethylcarbodiimide 
hydrochloride (EDAC) and bovine serum albumin (BSA) were 
obtained from Sigma; acetic acid was obtained from Carlo Erba; 
N-hydroxysuccinimide (NHS) and creatinine were obtained from 
Fluka; Phosphate Buffered  Saline (PBS) tablets were obtained 
from Amresco; hCG  protein was  purchased  from  Abcam  (UK);  
anti-hCG  antibody was supplied by Ig Innovations (affinity 
constant for hCG of 2.9 x 1010 1/M, where M is 0.03 nM); 
ammonium chlo- ride and calcium chloride were obtained from 
Merck; sodium dihydrogen phosphate was obtained from Schar- 
lau; potassium sulfate and sodium chloride were obtained from 
Panreac; and urea was obtained from     Fragon. 
Firstly,  a  1 %  (v/v)  acetic  acid  solution  was  prepared  in 
deionised water. Chitosan was then added to obtain 0.1 % (w/w)   
solution.   Finally,   AuNPs   were   also   added   (as bought   
from   Sigma   or   else   prepared   from   gold   in   5– 50 nm  size)  
to  obtain  a  1 %  (v/v).  PBS  solution  was  pre- pared  by  
dissolution  of  1  tablet  of  PBS  in  100 mL  of  de- ionised  water.  
EDAC,  NHS  and  antibody  solutions  were prepared  in  this  
buffer.  Synthetic  urine  was  prepared  by mixing several 
individual solutions leading to a final com- position  of  5 x 10-6  
M  urea,  5.3 x 10-6  M  creatinine,  9.8 x 10-7  M magnesium 
chloride, 6.8 x 10-7  M calcium chloride, 
3.2 x 10-6  M   sodium   dihydrogen   phosphate,   3.3 x 10-6  M 
ammonium   chloride,   3.9 x 10-6  M   potassium   sulfate   and 
  
6.5 x 10-6  M  sodium  chloride.  A  redox  probe  solution  was 
prepared   in   PBS   buffer   and   had   a   concentration   of 
5.0 mmol/L      of      [Fe(CN)6]
3-        and      5.0 mmol/L      of 
[Fe(CN)6]
4-. 
 
 
2.2 Apparatus 
Electrochemical measurements were conducted with a po- 
tentiostat/galvanostat, Metrohm Autolab, PGSTAT302N, controlled 
by Nova software and equipped with a Fre- quency Response 
Analysis module. Graphene-SPEs were purchased from DropSens 
(DRP-110GPH) and were composed of a carbon counter electrode, 
an Ag pseudo- reference electrode, and a printed graphene  
working    elec- 
trode   (1 = 4 mm).   Electrical   characterization   of   SPEs 
was performed by connecting the SPEs to the potentio- 
stat/galvanostat via a suitable switch box   (DropSens). 
FTIR measurements were performed using an infrared 
spectrometer from Thermo Scientific, Smart iTR, Nicolet iS10, 
coupled to an Attenuated Total Reflectance (ATR) accessory  also   
from   Thermo   Scientific,   equipped   with a  Germanium  sample 
holder. 
 
 
2.3 Procedures for Immunosensor Assembly 
The  chitosan  (CS)  film  was  obtained  by  electrodeposition of 
chitosan on the graphene-SPE surface using chronoam- 
perometry  (CA).  The  three-electrodes  of  the  SPE  were 
covered  by  a  solution  of  0.1 %  of  chitosan  and  1 %  of 
AuNPs. A potential of -2.5 V was applied for 120 s. 
A drop of activated antibody solution was then cast over the 
CS-AuNPs film on the working electrode, and incubated for 2 
hours, at room temperature. The activated 
antibody solution had been pre-prepared, by incubating a 200 
mg/mL antibody solution in 25 mmol/L EDAC and 50 mmol/L 
of NHS, for 2 hours, at room temperature. Fol- lowing exposure 
of the working electrode to the activated 
antibody solution the working electrode was then thor- oughly 
rinsed with PBS  and  incubated  in  BSA  solution (0.5 mg/mL in 
PBS buffer) solution, for 30 minutes. The immunosensor  was  
finally  washed  with  PBS  buffer    and 
kept at 48C before use. 
 
 
2.4 Human Chorionic Gonadotropin Binding 
hCG binding to the immobilized antibody was achieved by 
placing a drop of hCG solution on the immunosensor working 
electrode surface. Different concentrations of hCG solutions, 
ranging from 0.01 to 100 ng/mL, were pre- pared by dilution of 
the 250 ng/mL standard hCG solu- tions in PBS or synthetic 
urine. hCG was also detected in real urine samples from 
pregnant women. A period of 20 minutes was allowed for 
antigen/antibody binding. This was followed by PBS 
washing prior to redox probe EIS measurements. 
2.5 Electrochemical Assays 
 
CV  and   EIS   assays   were   conducted   in   triplicate.   CV 
measurements     were     conducted     in     5.0 mmol/L     of 
[Fe(CN)6]
3-   and  5.0 mmol/L  of  [Fe(CN)6]
4-,  prepared  in 
PBS  buffer,  pH 7.4,  using  a  potential  scan  from  -0.7  to 
+ 0.7 V, at 50 mV/s. EIS assays were made using the same 
redox couple [Fe(CN)6]3-/4-  solution, at a standard poten- tial  
of  + 0.10 V,  using  a  sinusoidal  potential  perturbation with 
amplitude of 100 mV and a frequency of 50 Hz, loga- 
rithmically distributed over a frequency range of 100 000– 
0.1 Hz. Impedance data was fitted to a R(RC) circuit, the simplified 
Randles circuit, using the Nova Software. This circuit included 
solution resistance (RS), double layer ca- pacitor (Cdl), and charge 
transfer resistance (Rct) compo- nents, where double-layer 
capacitance and charge-transfer resistance are in parallel  [48]. 
The immunosensor response to varying hCG concen- trations 
was assessed by EIS measurements. The hCG sol- utions ranged 
from 0.01 to 100 ng/mL, and were prepared either in PBS buffer 
pH 7 or in synthetic urine. The LOD was the hCG 
concentration at which the calibration curve corresponded to a 
signal of 3 s, where s is the standard deviation of EIS blank 
signals (obtained in the absence of the  hCG). 
 
3 Results and Discussion 
3.1 Immunosensor Assembly 
The first surface modification step consisted of electro- chemical 
oxidation of the graphene support. This  oxida- tion produced a 
clean and reproducible  surface,  contain- ing  several  hydroxyl  
groups  (Figure 1 A).  Hydroxyl groups display a high 
electrostatic affinity to amine-based materials such as CS, due to 
inherent electrostatic interac- tions predominantly in hydrogen   
bonding. 
The solution of CS and AuNPs was then electrodeposit- ed 
over the oxidized graphene (Figure 1 B), yielding an amine-
terminated layer. Deposition of CS, as  a  method for producing 
an amine  surface  was  tested  in several ways, from drop-casting 
to electrodeposition, with or without  AuNPs.   Some   of   the   
conditions   tested  yielded a degraded graphene surface, with 
graphene flakes de- taching into solution and destroying the  
working  area of the SPE. Optimised conditions led to a stable 
working electrode  area  modified  with  CS  and AuNPs. 
Following deposition of the CS/AuNP layer, the Ab is 
attached to the CS via its NH2 groups (Figure 1 C). This was 
achieved by activating the -COOH groups at the Fc terminal 
of the antibody to orientate it on the sensor plat- form, with the 
highest probability of having all binding sites accessible for 
antigen binding. This activation was made using conventional 
EDAC/NHS chemistry: (1) re- action of -COOH with 
EDAC forms a O-acylisourea in- termediate that 
subsequently reacted with NHS to pro- duce a more stable 
active ester; (2) this ester undergoes nucleophilic substitution 
with any amine group on  the 
  
 
Fig. 1.     Schematic illustration of the immunosensor  assembly. 
 
 
surface, resulting in the formation of an amide bond and 
subsequent covalent linkage of the antibody to the bio- sensor [49]. 
Any unbound protein was removed from the surface by thorough 
washing with PBS    buffer. 
The final stage of the sensor assembly was devoted to blocking 
any free NH2 binding sites on the surface  that could participate in 
non-specific  binding.  This  was  done by adding BSA (Figure 1 
D), a common protein  in biolog- ical fluids. BSA interacts with 
any  available  protein bind- ing site, blocking these binding sites  
to  side-proteins  in real samples. This reaction also contributed  to 
deactivat- ing carboxylic positions, thereby eliminating side-
respons- es from the  immunosensor. 
 
The binding event between hCG and the immunosen- sor 
antibody is the final stage of the device development (Figure 1 
E). This event is detected electrochemically. A mathematical 
relation between the analyte concentration and the obtained 
electrical signal was derived. 
 
3.2 Electrochemical Follow-Up of the Immunosensor 
Chemical modifications taking place at the graphene sur- face 
were followed by EIS (Figure 2), by monitoring the changes in the 
electron transfer properties of  the  iron redox probe [50]. EIS data 
was recorded in the form of Nyquist plot, showing the frequency 
response  of the     elec- 
 
 
 
Fig. 2.     EIS  spectra  of  each  stage  of  the  assembly  of  the  immunosensor  (A)  and  CV  data  taken  at  each  stage  (B).  (A)  Nyquist  
plots of  BSA/anti-hCG/CS/graphene-SPE  sensor,  obtained  in  5.0 mM  [Fe(CN)6]3-/4-  PBS  buffer  pH 7.4.  (B)  CV  record  after  
modification of chitosan/AuNPs/graphene-SPE with antibody and BSA. 
  
trode/electrolyte system and an area plot of the imaginary 
component  (-Z’’)  of  the  impedance  against  the  real  com- ponent  
(Z’).  The  Rct   at  the  electrode  surface  is  given  by the  
semicircle  diameter  of  obtained  in  Nyquist  plot  and was  used  
to  define  the  interface  properties  of  the  elec- trode. 
The nonmodified graphene-SPEs showed a very small 
semicircle at the  Nyquist  plot,  indicating  the  presence of a very 
fast electron-transfer process on the graphene sup- port (Figure 2 
A). Subsequent deposition of a  CS/AuNPs film contributed to  an  
increase  in  the  Rct,  thus  acting  as a barrier to the electron 
transfer of the redox probe. This increase  is  small   but   
consistent   with   the   presence  of a polymeric material that has a 
small fraction  of protonat- ed amine functions  (bearing  the  
opposite  charge  to  that of the redox probe) and AuNPs included 
in its matrix. Subsequent antibody and BSA binding, both protein 
ma- terials, generated an additional increase in the Rct, indi- cating  
as  an  additional  barrier  to  electron  transfer    pro- 
cesses. All CV assays supported the results of EIS studies 
(Figure 2 B), with decreased current peaks after protein binding 
and an increase in the peak-to-peak potential separation. 
 
3.3 Qualitative Analysis of the Immunosensor Surface 
Figure 3 shows the FTIR spectra of the different stages of 
assembly of the immunosensor on graphene-SPEs. The bare 
graphene spectra displayed very small intensity and no 
significant band/peak was observed (pink line). 
The  presence  of  CS  on  graphene  after  electrodeposi- tion    
is    shown    by    the    adsorption    peak    centred    at 3362 cm-1    
(blue   line),   corresponding   most   probably   to a  combination  
of  both  O-H  and  N-H  stretching  and  in- termolecular  
hydrogen  bonding  within  CS  molecules  [51– 53] .   Although   
O-H   stretching   is   expected   to   lead   to a  very  intense  
absorption  peak,  the  amount  of  CS  on  the surface is probably  
too small for this observation. The CS 
 
 
 
 
Fig. 3.    FTIR spectra of the graphene-SPEs and graphene modified with CS and antibody/antigen (spectra on the right correspond to 
a smaller range of wavenumber, focusing the transmittance range of interest). 
  
film  on  graphene  also  shows  two  small  peaks  lying  within 2850–
2950 cm-1  that corresponded to C-H stretching. 
The presence of antigen and antibody on graphene/CS 
contributes to additional light absorption. No peak is evi- 
denced on the corresponding spectra (purple), which is probably a 
consequence of the low transmittance ob- served, being close to 
saturation (almost no light is trans- mitted). Overall, this spectra 
confirms the presence of an additional  layer  over CS. 
 
 
 
 
3.4 Analytical Performance 
Figure 4 A shows the Nyquist plots of the immunosensor as a 
function of increasing hCG concentrations. The con- 
centration range of hCG used for calibration ranged from 
0.1 to 25 ng/mL, with all solutions prepared in PBS. The 
corresponding calibration curve was plotted as Rct (ex- tracted 
from the Nyquist plots) against  the  logarithm  of the hCG 
concentration (Inset of  Figure 4 A).  Overall,  the Rct increased 
logarithmically  over  the  tested concentra- tion  range.  The  
average  slope  of  the  Rct   versus   log[hCG, 
ng/mL] was 0.129 kW/decade hCG with an R2  correlation 
coefficient of 0.95. LOD was 0.016 ng/mL. 
The analytical response of the immunosensor was con- sidered 
irreversible, probably related to the high affinity between  hCG  
and  its antibody. 
The  sensor  was  always  produced  in  one  day,  kept   at 4 8C 
and analysed in  the  following  day.  Thus,  it  can  be said that it 
was stable for 24 hours,  but  longer  periods may be found when 
stored at 4 8C (as other immunosen- sors). 
3.5 Selectivity of the Sensor 
 
Sensor selectivity was assessed by evaluating the sensor 
response to the combined effect of any nonspecific com- 
pounds present in the samples analysed. This was done by 
calibrating the immunosensor-SPE in synthetic urine [54] and 
assessing any changes within the analytical perfor- mance of the 
device. Figure 4 B shows the Nyquist plots obtained in this 
context. Unexpectedly, the performance of the device 
improved, showing a wider log[hCG] re- sponse range and 
increased sensitivity. The linear re- sponse ranged from 0.1 to 5 
ng/mL and the average slope 
was of 0.353 kW/decade. 
Overall, the analytical performance of the  immunosen- sor was 
unexpectedly enhanced. Although this may indi- cate interference 
in the electrical response of the immu- nosensor by changing the 
medium in which it was evalu- ated, the existence of  a  linear  
range  in  the  response  of the electrode suggested  that  a  
successful  application  of the device in real urine samples could 
be achieved. 
 
3.6 Application to Urine Samples 
The values of hCG in real urine samples were determined by 
EIS measurements after previous calibration of the device in real 
urine of non-pregnant women. The typical Nyquist plots obtained 
are shown in Figure 5,  along with the  corresponding  calibration 
curve. 
The device exhibited a  linear  logarithmic  behaviour from 0.01 
to 1 ng/mL, a narrower concentration range of linear logarithmic 
response than that observed with syn- thetic urine. The biggest 
difference in terms of analytical performance   was   reflected   in   
the   signal   saturation   at 
 
 
 
Fig. 4.     Calibration   curve   of   the   immunosensor.   (A)   Nyquist   plots   of   BSA/anti   hCG/chitosan/graphene-SPE   sensor,   in   5.0 
mM [Fe(CN)6]3-/4-  PBS  buffer  pH 7.4,  previously  incubated  in  increasing  concentrations  of  hCG.  (B)  Nyquist  plots  of  
BSA/anti-hCG/chi- tosan/graphene-SPE  sensor,  in  5.0 mM  [Fe(CN)6]3-/4-   synthetic  urine  pH 6.5,  previously  incubated  in  
increasing  concentrations  of hCG. 
  
 
Fig. 5. Nyquist plots corresponding to the calibration of the immunosensor in real urine samples with hCG standards in ng/L. Inset: 
corresponding  calibration  curve,  plotting  log(hCG)  against Rct. 
 
 
lower hCG concentrations. Ever so, the format of the Rct curve 
was similar to that of the calibration standards (Figure 5), 
suggesting that the system was operating well when using real 
urine  samples. 
A pristine but unused immunosensor was then used to 
analyse the urine of a pregnant woman, with a pregnancy of 3 
to 5 weeks. The concentration of hCG obtained was 
3.5 ng/mL (17.4 mIU/mL), which was in agreement with the 
pregnancy status. 
 
4 Conclusions 
In summary, a new impedimetric biosensor for hCG de- 
termination in urine has been developed. A simple ap- 
proach for generating a graphene-amined surface to which an 
antibody binding with a suitable orientation for antigen binding 
is presented. The observed resistance to electron transfer 
increased linearly with increasing of log- (hCG) concentration. 
The sensor response varied with  the  background medium used 
to calibrate the system and with the varia- tions of blank 
immunosensor devices produced similarly. Once the 
immunosensor variability is eliminated by using relative 
impedance data (corrected against the blank, or zero 
concentration), the slopes become 0.371; 0.572 and 0.358, in 
buffer, synthetic urine and real urine. Therefore, only synthetic 
urine changed the typical calibration fea- tures. No plausible 
explanation for such differences in synthetic urine, apart from the 
eventual presence of some compound that may interact with the 
antibody directly (thereby changing its binding affinity for the 
antigen) and the pH differences between the matrices used in 
the cali- bration. However, if the  background  composition  be- 
tween samples and standards  are  tuned,  no  problem exists in the 
application of the immunosensor to the anal- ysis of real samples, 
as proven by our   results. 
Overall, the sensor has been applied successfully to 
quantitatively    detect    hCG    in    the    urine    of   pregnant 
women, suggesting a successful  application  in point-of- care 
diagnostics  in the near  future. 
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